These findings suggest that IL-33–mediated amelioration of colitis might not be associated with an enhanced Treg response in our mouse colitis models different from previous studies27–29, implying that other factors might contribute to the tissue protection observed after mrIL-33 treatment of colitis. This evidence concerns the gene IL33 and colitis.